In this study, we used the HFD mouse model, shown to provide similar metabolic context as in human NASH 31, to evaluate the effectiveness of the specific MD2 inhibitor, L6H21, in reducing inflammatory liver injury. The gene discussed is LY96; the disease is metabolic dysfunction-associated steatohepatitis.